Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorChemical name: N-alpha-(9-Fluorenylmethyloxycarbonyl)-1-adamantyl-L-glycine // Synonyms: Fmoc-Gly(1-adamantyl)-OH, (S)-Fmoc-1-adamantyl-glycine, (S)-2-{[(9-fluorenyl)methyloxycarbonyl]amino)-2-(adamantan-1-yl)acetic acid, Fmoc-Gly(adamantyl)-OH
from $168.75
Building block of choice, whenever a bulky, hydrophobic residue is required.
Tumor-Cell-Targeted Methionine-enkephalin Analogues Containing Unnatural Amino Acids: Design, Synthesis, and in Vitro Antitumor Activity; S. Horvat, K. Mlinariæ-Majerski, L. Glavaš-Obrovac, A. Jakas, J. Veljkoviæ, S. Marczi, G. Kragol, M. Rošèiæ, M. Matkoviæ, A. Milostiæ-Srb; J. Med. Chem. 2006; 49(11): 3136-3142. https://doi.org/10.1021/jm051026+.
An Adamantyl Amino Acid Containing Gramicidin S Analogue with Broad Spectrum Antibacterial Activity and Reduced Hemolytic Activity; V. V. Kapoerchan, A. D. Knijnenburg, M. Niamat, E. Spalburg, A. J. de Neeling, P. H. Nibbering, R. H. Mars-Groenendijk, D. Noort, J. M. Otero, A. L. Llamas-Saiz, M. J. van Raaij, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Chem. Eur. J. 2010; 16(40): 12174-12181. https://doi.org/10.1002/chem.201001686.
Tuning hydrophobicity of highly cationic tetradecameric Gramicidin S analogues using adamantane amino acids; A. D. Knijnenburg, V. V. Kapoerchan, E. Spalburg, A. J. de Neeling, R. H. Mars-Groenendijk, D. Noort, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Bioorg. Med. Chem. 2010; 18(23): 8403-8409. https://doi.org/10.1016/j.bmc.2010.09.018.
‘Inverted’ analogs of the antibiotic gramicidin S with an improved biological profile; V. V. Kapoerchan, A. D. Knijnenburg, P. Keizer, E. Spalburg, A. J. de Neeling, R. H. Mars-Groenendijk, D. Noort, J. M. Otero, A. L. Llamas-Saiz, M. J. van Raaij, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Bioorg. Med. Chem. 2012; 20(20): 6059-6062. https://doi.org/10.1016/j.bmc.2012.08.038.
Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality; K.-Y. Hung, P. W. R. Harris, A. Desai, J. F. Marshall, M. A. Brimble; Eur. J. Med. Chem. 2017; 136: 154-164 . https://doi.org/10.1016/j.ejmech.2017.05.008.
Structure-Based Design of Non-natural Macrocyclic Peptides That Inhibit Protein-Protein Interactions; D. M. Krüger, A. Glas, D. Bier, N. Pospiech, K. Wallraven, L. Dietrich, C. Ottmann, O. Koch, S. Hennig, T. N. Grossmann; J. Med. Chem. 2017; 60(21): 8982-8988. https://doi.org/10.1021/acs.jmedchem.7b01221.
J. Müller, R. A. Kirschner, J.-P. Berndt, T. Wulsdorf, A. Metz, R. Hrdina, P. R. Schreiner, A. Geyer, G. Klebe; ChemMedChem 2019; 14: 663-672. https://doi.org/10.1002/cmdc.201800779.
Please send me more information about